Recent Updates
Recently added Catalysts
ADMA Negative Sentiment Score: 20/100

ADMA INVESTIGATION NOTICE: ADMA Biologics Stock Plummets 20% after Auditor Resigns; Investors are Notified to Contact BFA Law (Nasdaq:ADMA)

Key Takeaway: ADMA Biologics, Inc. is facing an investigation by Bleichmar Fonti & Auld LLP for potential violations of federal securities laws after the unexpected resignation of its auditor, CohnReznick LLP. This development has led to a significant decline in ADMA's stock price, which fell by over 20%. Investors are encouraged to seek legal options regarding their investments amidst this crisis, which reflects serious concerns about the company's financial governance and future stability.

Market Sentiment Analysis

CONCERNS & RISKS

  • ADMA Biologics experienced a surprise resignation of its independent auditor, leading to financial instability.
  • The company's stock plummeted more than 20%, signaling investor fear and loss of confidence.
  • An investigation into potential violations of federal securities laws has been announced, posing further risks.

Full Press Release Details

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws.
If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc.
Why Did ADMA Biologics’s Stock Drop?
ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, markets and develops specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases.
On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.
The news has caused a precipitous decline in the price of ADMA Biologics stock. During trading on October 10, 2024, the price of ADMA Biologics stock declined more than 20%.
If you invested in ADMA Biologics you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
Attorney advertising. Past results do not guarantee future outcomes.

Tags

Frequently Asked Questions

What is the recent issue facing ADMA Biologics?

ADMA Biologics is under investigation for possible federal securities law violations.

Why did ADMA Biologics's stock drop recently?

The stock dropped over 20% following the unexpected resignation of its auditor.

Who is investigating ADMA Biologics?

The law firm Bleichmar Fonti & Auld LLP is conducting the investigation.

How much did ADMA's stock decline on October 10, 2024?

The stock price declined more than 20% during trading on that day.

Are there legal options for ADMA Biologics investors?

Yes, investors may have legal options and can submit their information for assistance.

Last updated: Oct 29, 2024